Serstech AB

Serstech AB

SSTO:SERT
0.51
SEK
+0.01
(+1.20%)
-0.11EPS
113.93MMarket Cap
Nov 10Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.02
0.04
0.08
0.28
0.27
0.13
0.21
0.23
0.19
0.17
0.3
0.23
0.16
0.12
Basic EPS, GAAP
-0.14
-0.31
-0.24
-0.1
-0.04
-0.15
-0.18
-0.08
-0.1
-0.29
- -
-0.04
-0.12
-0.11
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
-0.18
-0.12
-0.13
-0.21
-0.01
-0.04
-0.15
-0.13
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.62
0.51
0.69
0.6
0.56
0.51
0.58
0.5
0.56
0.27
0.23
0.32
0.19
0.14
Tangible Book Value per Share
0.23
-0.14
-0.14
0.07
- -
0.1
0.24
0.1
0.15
-0.08
0.08
0.19
0.06
0.02
Basic Weighted Avg Shares
25
28
34
61
61
82
88
88
100
100
207
228
244
254
Sales/Revenue/Turnover
- -
1
3
17
17
11
19
20
19
17
63
52
39
30
Operating Margin (%)
-723.39
-735.86
-289.6
-33.91
-13.8
-129.92
-86.79
-34.66
-57.24
-180.88
-1.62
-17.11
-73.95
-90.87
Depreciation Expense
- -
- -
2
4
4
4
10
9
7
8
12
8
8
9
Net Income, GAAP
-4
-8
-8
-6
-3
-12
-16
-7
-10
-30
1
-9
-29
-29
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
4.92
- -
- -
- -
Profit Margin (%)
-721.46
-742.34
-300.52
-36.68
-15.16
-116.46
-83.67
-32.85
-54.96
-172.78
1.14
-17.47
-75.84
-95.51
Working Capital
6
-2
-3
6
1
9
22
10
15
-4
17
35
17
6
LT Debt
- -
2
2
2
2
1
1
1
- -
4
- -
- -
- -
- -
Total Equity
16
14
24
37
34
42
51
44
56
27
48
77
48
36
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
2.23
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
2.43
- -
- -
- -
Return on Common Equity (%)
-30.67
-56.59
-43.1
-21.14
-7.14
-32.14
-33.59
-14.18
-20.51
-71.48
1.92
-14.66
-47.08
-57.79

Capital Structure

SEK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
- -
- -
10
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
254
254
254
Market Capitalization
145
93
114

Working Capital

SEK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
25
19
27
Cash, Cash Equivalents & STI
10
1
4
Accounts Receivable, Net
6
8
8
Inventories
7
8
11
Total Current Liabilities
8
9
21
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
10
Deferred Revenue
- -
- -
- -

Growth Rates

SEK

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
15.59%
15.51%
-37.58%
Free Cash Flow
- -
169.24%
340.46%
Net Income, GAAP
-74.5%
-203.6%
220.6%
Sales/Revenue/Turnover
80.05%
41.47%
-26.15%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
14
21
3
13
52
2025
20
5
8
6
39
2026
7
10
- -
- -
- -

Quarterly Earnings Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.02
-0.04
-0.02
-0.04
2025
-0.01
-0.04
-0.03
-0.04
-0.12
2026
-0.03
-0.02
- -
- -
- -

Quarterly Dividends Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Stefan Sandor
Full Time Employees
26
Sector
Electronic technology
Industry
Aerospace & defense
Address
Aldermansgatan 13 Lund SN Sweden 227 64
IPO Date
Aug 29, 2013
Business
Serstech AB develops and manufactures handheld Raman spectrometers and related software for rapid chemical identification, primarily serving safety and security sectors including law enforcement, customs, first responders, hazmat teams and military operations. The company offers core products such as the Serstech Arx mkII, a one-hand operated device with patented autofocus for identifying narcotics, explosives, toxic industrial chemicals, biotoxins and chemical warfare agents through packaging; Serstech Arx and Arx+ models for precise substance detection; the patented SERS kit enabling identification of low-concentration and fluorescent samples like heroin; Serstech 100 Indicator with Heroin ID Kit for security applications; and ChemDash software with substance libraries for data analysis and compliance, including FDA-compliant versions targeting pharmaceutical and life-science markets for verifying incoming goods non-destructively. Founded in 2006 and headquartered in Lund, Sweden, Serstech conducts all design, development and production in Sweden, with a U.S. office in Key Largo, Florida, and distributes globally through partners in North America, Asia, Europe and Latin America. Recent developments include transitioning to in-house production alongside third-party facilities to enhance capacity, resilience and cost efficiency with significant COGS reductions; doubling the sales team to six professionals to accelerate growth; launching upgraded Serstech 100 Indicator and ChemDash for pharmaceuticals in 2024; closing the Romanian office to consolidate operations in Lund; securing multiple partner orders such as 5.6 MSEK from Proengin Inc., 12.4 MSEK and 10 MSEK from Singapore, 9.7 MSEK from Chilean partner Aerotech, 1.9 MSEK from Field Forensics and others totaling over 40 MSEK in 2024-2025; and recruiting a new Chief Commercial Officer and Chief Financial Officer.